Ralfate 500 Tablet

About Ralfate 500 Tablet

The tablet Ralfate 500 contains Sucralfate and is made by Opsonin Pharma Limited. It is not recommended for children, and a doctor should confirm whether it is appropriate for your condition.

There are 15 brands of Sucralfate listed in Bangladesh. The lowest listed price is Antepsin 1000 mg Tablet at ৳ 5.52 per unit.

What is Ralfate 500 Tablet?

Ralfate 500 500 mg tablet is a medicine made by Opsonin Pharma Limited. It forms a protective coating at the site of an ulcer, and it also reduces the action of pepsin and bile. Sucralfate is a chelating complex that is only minimally absorbed from the gastrointestinal tract. Use it only as your doctor directs.

Uses of Ralfate 500

It is not recommended for children, and a doctor should confirm whether it is appropriate for your condition. Sucralfate works at the ulcer surface to form a protective barrier and reduce the action of pepsin and bile. It is also used to help prevent gastrointestinal bleeding caused by stress ulcers in seriously ill patients. The doctor decides the dose and how long it should be taken.

How to use Ralfate 500

Take Ralfate 500 500 mg tablet exactly as your doctor tells you. Swallow the tablet with water. Ralfate 500 is taken by mouth. The dose and schedule depend on your condition and are decided by your doctor; never change them on your own. Do not change the dose or stop early on your own.

Side effects of Ralfate 500

Some people may notice headache, nausea, abdominal pain, constipation, diarrhoea or urticaria (hives). Some patients may form bezoars, especially those with delayed gastric emptying or those receiving tube feeds. Headache was the most common in reported cases, followed by nausea, abdominal pain, constipation, diarrhoea and urticaria. Contact your doctor if you notice anything unusual after taking it. Tell your doctor if you notice any side effect.

Safety and precautions

Do not take Ralfate 500 500 mg tablet if you are allergic to Sucralfate. Before using Ralfate 500 500 mg tablet, tell your doctor if you are pregnant, planning pregnancy, or breastfeeding, because safety in pregnancy has not been established and it is not known if Sucralfate passes into breast milk. It is contraindicated if you are allergic to Sucralfate. Ask your doctor first if any of these apply.

Frequently asked questions

What is Ralfate 500 used for?

It is not recommended for children, and a doctor should confirm whether it is appropriate for your condition. Sucralfate works at the ulcer surface to form a protective barrier and reduce the action of pepsin and bile.

How do I use Ralfate 500 correctly?

Take Ralfate 500 500 mg tablet exactly as your doctor tells you. Swallow the tablet with water.

Can Ralfate 500 cause side effects?

Some people may notice headache, nausea, abdominal pain, constipation, diarrhoea or urticaria (hives). Some patients may form bezoars, especially those with delayed gastric emptying or those receiving tube feeds.

Who should be careful with Ralfate 500?

Do not take Ralfate 500 500 mg tablet if you are allergic to Sucralfate. Before using Ralfate 500 500 mg tablet, tell your doctor if you are pregnant, planning pregnancy, or breastfeeding, because safety in pregnancy has not been established and it is not known if Sucralfate passes into breast milk.

Indications

Sucralfate is indicated in adults and adolescents over 14 years old for treatment of-
  • Duodenal ulcer
  • Gastric ulcer
  • Chronic gastritis
  • The prophylaxis of gastrointestinal hemorrhage from stress ulceration in seriously ill patients.

Pharmacology

Sucralfate is non-systemic as the drug is only minimally absorbed from the gastrointestinal tract. The minute amount which absorbed primarily excretes in the urine. Sucralfate promotes the healing of gastric and duodenal ulcers by the formation of a chemical complex that binds to the ulcer site to establish a protective barrier. Besides, Sucralfate inhibits the action of pepsin and bile.

Dosage & Administration

Duodenal ulcer, gastric ulcer, chronic gastritis-
  • Adults: The usual dose is Sucralfate 2 gm twice daily to be taken on rising and at bedtime or Sucralfate 1 gm four times a day to be taken 1 hour before meals and at bedtime. Maximum daily dose is 8 gm but up to twelve weeks may be necessary in resistant cases.
  • Pediatric population: The safety and efficacy of Sucralfate in children under 14 years of age has not been established.
  • Elderly: There are no special dosage requirements for elderly patients but as with all medicines the lowest effective dose should be used.
Prophylaxis of gastrointestinal hemorrhage from stress ulceration-
  • Adults: The usual dose is Sucralfate 1 gm orally or via a nasogastric tube 4 to 6 times a day. To prevent clogging of the nasogastric tube flush with 10 ml of water following each administration. The duration of treatment for prophylaxis of stress ulceration must be individually determined. Treatment should be continued for as long as one or more of the risk factors for stress ulceration is present but normally not for more than 14 days.

Interaction

Concomitant administration of Sucralfate may reduce the bioavailability of certain drugs including Fluoroquinolones such as Ciprofloxacin and Norfloxacin, Tetracycline, Ketoconazole, Sulpiride, Digoxin, Warfarin, Phenytoin, Theophylline, Levothyroxine, Quinidine, and H2 antagonists. The bioavailability of these agents may be restored by separating the administration of these agents from Sucralfate by two hours. This interaction appears to be non-systemic in origin presumably resulting from these agents being bound by Sucralfate in the gastrointestinal tract. Because of the potential of Sucralfate to alter the absorption of some drugs from the gastrointestinal tract, the separate administration of Sucralfate from that of other agents should be considered when alterations in bioavailability are felt to be critical for concomitantly administered drugs. Sucralfate should not be co-administered with citrate preparations. Co-administration citrate preparations with sucralfate may increase the blood concentrations of aluminium. The mechanism may be due to the chelation of aluminium which is assumed to increase its absorption. The administration of Sucralfate   1 g and enteral feeds by nasogastric tube should be separated by one hour in patients receiving Sucralfate 1 g for the prophylaxis of stress ulceration. In rare cases, bezoar formation has been reported when Sucralfate and enteral feeds have been given too closely together.

Contraindications

Sucralfate tablet and suspension are contraindicated in patients with hypersensitivity to sucralfate.

Side Effects

The most common adverse event was headache (3.4%) followed by nausea (2.3%), abdominal pain (2.3%), constipation (1.1%), diarrhea (1.1%), and urticaria (1.1%). The majority of patients who reported bezoars, had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. Episodes of hyperglycemia have been reported in diabetic patient.

Pregnancy & Lactation

Safety in pregnant women has not been established and Sucralfate should be used during pregnancy only if clearly needed. It is not known whether this drug is excreted in human milk. Caution should be exercised when Sucralfate is administered to breast-feeding women.

Precautions & Warnings

Sucralfate should only be used with caution in patients with renal dysfunction, due to the possibility of increased aluminium absorption. Sucralfate is not recommended for use in individuals on dialysis. In patients with severe or chronic renal impairment, Sucralfate should be used with extreme caution and only for short-term treatment. Small amounts of aluminium are absorbed through the gastrointestinal tract and aluminium may accumulate. Aluminium osteodystrophy, osteomalacia, encephalopathy and anaemia have been reported in patients with chronic renal impairment. For patients with impairment of renal function, laboratory testing such as aluminium, phosphate, calcium and alkaline phosphatase is recommended to be periodically performed due to excretion impairment. The concomitant use of other aluminium containing medications is not recommended in view of the enhanced potential for aluminium absorption and toxicity. Bezoars have been reported after administration of sucralfate mainly to severely ill patients in intensive care units. The majority of these patients (including neonates in whom sucralfate is not recommended) had underlying conditions that may predispose to bezoar formation (such as delayed gastric emptying due to surgery, drug therapy or diseases that reduce motility) or were receiving concomitant enteral tube feeding.

Overdose Effects

In a clinical trial on healthy men of overdose with Sucralfate, most cases remained asymptomatic but symptoms of abdominal pain, nausea, and vomiting were reported in a few cases. Acute oral toxicity studies in animals using doses up to 12 gm/kg body weight could not find a lethal dose. Risks associated with overdose should therefore be minimal.

Storage Conditions

Store in a cool and dry place, protected from light.

Alternative brands of Sucralfate

Other brands with the same generic name, cheapest first.

See all 15 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.